Oncology Practice Reviews & Product and Research & Development Theater Opportunities ~Dallas

Venue: Hilton Anatole

Location: Dallas, TX., United States

Event Date/Time: Jun 18, 2010 End Date/Time: Jun 19, 2010
Registration Date: Jun 04, 2010
Report as Spam


This activity is presented by Physicians’ Education Resource in conjunction with Texas Oncology.

Oncology Practice Reviews is a 2-day symposium designed to educate community physicians on the state-of-the-art clinical management of a wide variety of solid tumors and hematologic malignancies. Lectures will highlight cutting-edge information and emerging treatment strategies for specific tumor types, including breast cancer, genitourinary malignancies, lymphoma, gastrointestinal malignancies, lung cancer, and multiple myeloma, in addition to other special topics unique to each meeting location. To enhance learning, participants will be engaged in solving “real-world” problems through practical, interactive, case-based presentations.

Product Theaters

Industry-led lectures and exhibits will be conducted in conjunction with this event to provide promotional product-specific information on available agents and products in development, respectively.

These optional activities are not certified for CME credit and are not planned or sanctioned by PER.


2201 Stemmons Frwy.
United States

Additional Information

Target Audience This educational program is directed toward medical oncologists and hematologists practicing in the community or academic setting who are interested in recent advances in the treatment of solid tumors and hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are also invited to attend. Learning Objectives At the conclusion of this symposium, you should be able to: Assess the efficacy and safety of targeted agents in the management of patients with solid tumors and hematologic malignancies Identify results of recent clinical trials that are currently applicable to the management of patients with solid tumors and hematologic malignancies